Is CYP2C19 destiny or just a small risk factor?

CYP2C19 is not destiny but a moderate risk factor, primarily for drug metabolism. This gene encodes an enzyme that metabolizes several medications, including clopidogrel (antiplatelet), proton pump inhibitors, and certain antidepressants. Variants like *2 and *3 reduce enzyme activity (poor metabolizers), increasing cardiovascular risk when using clopidogrel. Clinical guidelines (e.g., CPIC) recommend alternative therapy or dose adjustment for poor metabolizers. However, the effect is not absolute – other factors such as drug interactions, liver function, and diet also matter. For healthy individuals not taking relevant drugs, CYP2C19 status has little clinical impact. Consumer DNA tests often overstate its importance. Evidence is human-strong for clopidogrel but moderate for other drugs. A genetic result should be interpreted by a healthcare professional and not seen as a life sentence.